Breaking the Vicious Cycle of Antibiotic Killing and Regrowth of Biofilm-Residing Pseudomonas aeruginosa

Antimicrob Agents Chemother. 2018 Nov 26;62(12):e01635-18. doi: 10.1128/AAC.01635-18. Print 2018 Dec.

Abstract

Biofilm-residing bacteria embedded in an extracellular matrix are protected from diverse physicochemical insults. In addition to the general recalcitrance of biofilm bacteria, high bacterial loads in biofilm-associated infections significantly diminish the efficacy of antimicrobials due to a low per-cell antibiotic concentration. Accordingly, present antimicrobial treatment protocols that have been established to serve the eradication of acute infections fail to clear biofilm-associated chronic infections. In the present study, we applied automated confocal microscopy on Pseudomonas aeruginosa to monitor dynamic killing of biofilm-grown bacteria by tobramycin and colistin in real time. We revealed that the time required for surviving bacteria to repopulate the biofilm could be taken as a measure for effectiveness of the antimicrobial treatment. It depends on the (i) nature and concentration of the antibiotic, (ii) duration of antibiotic treatment, (iii) application as monotherapy or combination therapy, and (iv) interval of drug administration. The vicious cycle of killing and repopulation of biofilm bacteria could also be broken in an in vivo model system by applying successive antibiotic dosages at intervals that do not allow full reconstitution of the biofilm communities. Treatment regimens that consider the important aspects of antimicrobial killing kinetics bear the potential to improve control of biofilm regrowth. This is an important and underestimated factor that is bound to ensure sustainable treatment success of chronic infections.

Keywords: Pseudomonas aeruginosa; biofilm regrowth; biofilm treatment; killing kinetics; treatment optimization.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / blood
  • Anti-Bacterial Agents / pharmacokinetics
  • Anti-Bacterial Agents / pharmacology*
  • Biofilms / drug effects*
  • Biofilms / growth & development
  • Colistin / blood
  • Colistin / pharmacokinetics
  • Colistin / pharmacology*
  • Colonic Neoplasms / complications
  • Colonic Neoplasms / drug therapy*
  • Colonic Neoplasms / microbiology
  • Colonic Neoplasms / pathology
  • Colony Count, Microbial
  • Disease Models, Animal
  • Drug Administration Schedule
  • Drug Dosage Calculations
  • Drug Therapy, Combination / methods
  • Female
  • Mice
  • Mice, Inbred BALB C
  • Microbial Sensitivity Tests
  • Pseudomonas Infections / complications
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas Infections / microbiology
  • Pseudomonas Infections / pathology
  • Pseudomonas aeruginosa / drug effects*
  • Pseudomonas aeruginosa / growth & development
  • Pseudomonas aeruginosa / pathogenicity
  • Tobramycin / blood
  • Tobramycin / pharmacokinetics
  • Tobramycin / pharmacology*
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Tobramycin
  • Colistin